Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PRTC | US
-1.08
-4.67%
Healthcare
Biotechnology
31/03/2024
05/07/2024
22.03
23.98
23.98
22.03
PureTech Health plc a clinical stage biotherapeutics company engages in the discovery development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100 currently under Phase 3 stage to treat idiopathic pulmonary fibrosis (IPF); and LYT-200 a IgG4 monoclonal antibody currently under Phase 1/2 stage to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300 an oral allopregnanolone currently completed Phase 1 stage to treat depression anxiety and related indications; and LYT-310 an oral cannabidiol currently under preclinical stage to treat epilepsies and other neurological indications. In addition the company is developing LYT-503/IMB-150 a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis or bladder pain syndrome; and Glyph technology platform a lymphatic-targeting chemistry platform which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High Current Volume and Negative 1-Day Return
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
65.3%1 month
52.7%3 months
50.3%6 months
62.0%-
-
1.42
0.05
0.04
-11.14
235.65
-
-143.25M
527.22M
527.22M
-
-38.91K
61.50
-97.90
-13.25
9.02
0.05
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
6.36
Range1M
7.89
Range3M
10.95
Rel. volume
3.83
Price X volume
169.48K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Arcturus Therapeutics Ltd | ARCT | Biotechnology | 21.45 | 577.69M | -2.19% | n/a | 12.09% |
Mereo BioPharma Group plc | MREO | Biotechnology | 3.63 | 554.68M | 1.11% | n/a | 14.05% |
SIGA Technologies Inc | SIGA | Biotechnology | 7.74 | 550.49M | 0.00% | 6.90 | 0.79% |
Pharming Group N.V. | PHAR | Biotechnology | 8.13 | 547.51M | -3.56% | n/a | 78.41% |
PEPG | PEPG | Biotechnology | 16.84 | 545.91M | 0.96% | n/a | 11.04% |
Corbus Pharmaceuticals Holdings Inc | CRBP | Biotechnology | 50.31 | 537.65M | 1.31% | n/a | 17.83% |
Oculis Holding AG Ordinary shares | OCS | Biotechnology | 11.66 | 537.00M | -0.55% | 65.83 | 0.75% |
REGENXBIO Inc | RGNX | Biotechnology | 10.9 | 536.89M | 0.74% | n/a | 43.66% |
Adeptus Health Inc | ADPT | Biotechnology | 3.54 | 521.68M | 4.42% | n/a | 35.10% |
ORIC Pharmaceuticals Inc | ORIC | Biotechnology | 7.69 | 518.48M | 2.26% | n/a | 0.84% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.36 | 324.63M | -2.40% | 10.10 | 0.00% |
Latham Group Inc. | SWIM | Building Products & Equipment | 2.74 | 316.67M | -3.52% | 75.75 | 80.81% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.55 | 298.02M | -0.34% | 8.24 | 25.57% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 26.52 | 294.97M | -4.29% | 17.47 | -562.47% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 12.93 | 209.56M | -2.78% | 8.94 | 15.44% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 44.59 | 128.20M | -4.23% | 7.40 | 89.91% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -11.14 | -2.43 | Cheaper |
Ent. to Revenue | 235.65 | 4,101.76 | Cheaper |
PE Ratio | - | 41.26 | - |
Price to Book | 1.42 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 50.32 | 76.52 | Lower Risk |
Debt to Equity | 0.05 | 0.51 | Cheaper |
Debt to Assets | 0.04 | 0.24 | Cheaper |
Market Cap | 527.22M | 3.77B | Emerging |